|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Feb 09 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Genentech Places $1.7B Bet on RNAi Platform in SanegeneBio Pact
|
|
| | Lilly Strengthens Peptide Arsenal Through Global PepLib Discovery Alliance
|
|
| | PrimeGen’s $1.5B SPAC Merger Accelerates Regenerative Medicine Ambitions
|
|
| | Pfizer Moves PF-3944 Into Late-Stage Obesity Race After Strong Phase IIb Data
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Cover Story
|
| |
Lilly’s $3.5B U.S. Manufacturing Expansion
Domestic capacity, AI-enabled operations, and a $50B long-term U.S. production vision.
|
| |
Strategic Deals & Alliances
|
| |
| • | Ipsen × Origami Therapeutics: Landmark neurodegeneration deal in targeted protein degradation
|
|
| • | Genentech × SanegeneBio: $1.7B-potential RNAi licensing pact
|
|
| • | Lilly × Zonsen PepLib: Global peptide discovery collaboration
|
|
| • | MeiraGTx × ZipBio: AI-designed AAV gene therapy for Geographic Atrophy
|
|
| • | Biomica × Lishan Biotech: Global license for Phase I microbiome asset
|
|
| • | Eisai × Henlius: Serplulimab immuno-oncology expansion in Japan
|
|
| • | PrimeGen × DT Cloud Star: $1.5B SPAC merger powering regenerative medicine
|
|
| |
Clinical Trial & Pipeline Milestones
|
| |
| • | Sanofi: Positive Phase III results in Gaucher Disease Type 3
|
|
| • | Novo Nordisk: Phase III success for CagriSema in Type 2 Diabetes
|
|
| • | Pfizer: Strong Phase IIb obesity data for PF-3944
|
|
| • | Daiichi Sankyo: First patient dosed in CD37 ADC trial (B-cell NHL)
|
|
| • | Bayer: Phase III win for asundexian in secondary stroke prevention
|
|
| |
Regulatory & Approval Momentum
|
| |
| • | CHMP positive opinions: Rezurock, Kygevvi, Akeega, Zynyz
|
|
| • | FDA Priority Review: Datroway (TNBC)
|
|
| • | FDA NDA Acceptance: zanzalintinib + Tecentriq (mCRC)
|
|
| • | Breakthrough Therapy Designation: zovegalisib
|
|
| • | EC Approval: Nucala for COPD
|
|
| • | China NMPA Approvals/BTD: sacituzumab tirumotecan, ivonescimab combo
|
|
| |
MedTech & Diagnostics Advances
|
| |
| • | Natera: Signatera Cdx (MRD in bladder cancer)
|
|
| • | Quanterix: Blood test for Alzheimer’s diagnosis
|
|
| • | Hologic: FDA approval for Aptima HPV primary screening
|
|
| |
Biosimilars & Market Competition
|
| |
| • | Alvotech × Sandoz: Multi-region commercialization deals
|
|
| • | AVT80: Positive PK data for subcutaneous Entyvio biosimilar
|
|
| |
Digital Health & Early Detection
|
| |
| • | Hims & Hers × Galleri: Consumer access to multi-cancer early detection testing
|
|
| |
Animal Health
|
| |
| • | Boehringer Ingelheim: FDA EUA for Ivomec to prevent New World screwworm in cattle
|
|
| |
Industry Macro Trend
|
| |
| • | Precision Modalities Surge: Big pharma doubles down on degraders, RNAi, peptides, gene therapy, and AI-driven platforms.
|
|
| |
|
| |
PharmaShots Pharma Awards 2026
|
| |
|
| |
Celebrating Innovation and Excellence Across the Global Pharma & Healthcare Industry
|
| |
We are thrilled to announce the PharmaShots Pharma Awards 2026, a premier virtual event dedicated to recognizing groundbreaking innovation, leadership, and excellence in the pharmaceutical and healthcare sectors worldwide.
|
| |
This prestigious initiative brings together industry leaders, innovators, and key decision-makers from around the globe, creating a unique platform to celebrate achievements and set new benchmarks for the industry.
|
| |
Why Partner with PharmaShots Pharma Awards?
|
| |
Our sponsorship opportunities allow partners to:
|
| |
| • | Showcase your brand in front of a highly engaged, global pharma audience.
|
|
| • | Position your organization as a leader in innovation and thought leadership.
|
|
| • | Gain exclusive networking access to decision-makers, innovators, and influencers shaping the future of healthcare.
|
|
| |
We are currently reaching out to potential sponsors to understand your engagement goals and preferred sponsorship avenues. Based on your input, our team will provide a customized sponsorship prospectus detailing benefits, opportunities, and recommended next steps.
|
| |
Date of Announcement: May 1, 2026
|
| |
We invite organizations to join us in this landmark celebration. Your support will help us highlight excellence, inspire innovation, and strengthen connections across the global pharma ecosystem.
|
| |
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form, here
|
| |
|
| |
|
| |
Lilly’s $3.5B U.S. Manufacturing Expansion Sets a New Industry Benchmark
|
| |
|
| |
Strategic Investment & Manufacturing Vision
Eli Lilly is making a transformational bet on domestic production with a $3.5 billion investment in a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania — the largest life sciences investment in the state’s history. The site will produce next-generation injectable therapies, including the investigational weight-loss drug retatrutide, and is part of a broader push to strengthen U.S. manufacturing capacity.
|
| |
Economic & Workforce Impact
Construction is expected to begin in 2026, with operations slated by 2031. The project will create ~850 high-value permanent jobs for scientists, engineers, and technicians, and support ~2,000 construction roles during the build-out. State incentives, including up to $100 million in support and new workforce development programs, helped secure the project and underscore its economic significance.
|
| |
Strategic & Operational Strength
Lilly selected the site from 300+ applicants thanks to strong infrastructure, access to STEM talent, and regional logistics. The facility will incorporate advanced technologies from AI to machine learning to optimize operations and bolster supply reliability. Partnerships with local universities aim to grow talent pipelines.
|
| |
Macro Context
This Pennsylvania facility marks Lilly’s fourth U.S. manufacturing site announcement since early 2025 and fits within its broader $50 billion domestic expansion plan. It reflects a wider industry trend of reshoring production to meet booming demand for metabolic and biologic therapies while strengthening supply chains.
|
| |
|
| |
| | PrimeGen’s $1.5B SPAC Leap: Regenerative Medicine Heads to Nasdaq
|
|
|
|
|
| |
Billion-Dollar Biotech Bet: PrimeGen US Strikes $1.5B SPAC Merger with DT Cloud Star
|
| |
|
| |
PrimeGen US has signed a definitive business combination with DT Cloud Star at ~$1.5B implied equity value; H2 2026 close expected.
|
| |
Why It Matters
|
| |
| • | $1.5B Valuation: Provides public market access via SPAC for rapid capital raise.
|
|
| • | Nasdaq Listing: Enables growth funding for pipeline expansion.
|
|
| • | Regulatory Progress: FDA Pre-IND success de-risks liver disease program.
|
|
| • | Platform Momentum: Advances MSC/exosome tech to clinic.
|
|
| |
Strategic Focus
|
| |
| • | Capital Infusion: Funds Phase I/II trials in high-need liver indications.
|
|
| • | Public Profile Boost: Enhances PrimeGen’s visibility for partnerships/M&A.
|
|
| • | Regen Med Surge: Taps $50B+ cell therapy market amid exosome hype.
|
|
| • | Liver Disease Fit: Addresses unmet acute hepatitis failure needs.
|
|
| |
This merger positions PrimeGen for accelerated clinical/regulatory milestones, transforming it into a Nasdaq-listed regen med player.
|
| |
|
| |
| | Platform Power Plays: Big Pharma Doubles Down on Next-Gen Drug Modalities
|
|
|
|
|
| |
High-Stakes Bet on Protein Degradation: Ipsen Strikes Landmark Neurodegenerative Deal with Origami
|
| |
|
| |
Origami Therapeutics and Ipsen have entered a global collaboration and option agreement for a novel small-molecule protein degrader targeting a rare inherited neurodegenerative disorder, powered by Origami’s Oricision platform.
|
| |
Why It Matters
|
| |
| • | Global Option Rights: Ipsen controls worldwide development/commercialization after option exercise.
|
|
| • | Strong Economics: Upfront + multi-stage milestones and royalties for Origami.
|
|
| • | Tech Innovation: Oricision platform advances novel protein degraders for rare disorders.
|
|
| • | Strategic Momentum: Signals rising interest in targeted degradation for neurodegeneration.
|
|
| |
Strategic Focus
|
| |
| • | Pipeline Expansion: Bolsters Ipsen’s rare neuro portfolio with high-potential modality.
|
|
| • | Platform Validation: Positions Origami for more big-pharma partnerships in degraders.
|
|
| • | Market Opportunity: Taps growing targeted protein degradation sector (projected $10B+ by 2030).
|
|
| • | Unmet Need Alignment: Targets underserved rare neurodegenerative space with precision tech.
|
|
| |
This deal accelerates the program toward clinical stages, bolstering Ipsen’s rare disease pipeline and Origami’s platform validation.
RNAi Innovation Lands Global Backing: SanegeneBio and Genentech Forge $1.7B-Potential Pact
|
| |
SanegeneBio has signed a global licensing agreement with Genentech (Roche Group) for an RNAi therapeutic program using SanegeneBio’s proprietary RNAi platform.
|
| |
Why It Matters
|
| |
| • | Global Exclusive Rights: Genentech controls worldwide development/commercialization.
|
|
| • | Massive Economics: $200M upfront + $1.5B milestones + royalties for SanegeneBio.
|
|
| • | Tech Validation: Spotlights proprietary RNAi platform's potential.
|
|
| • | Deal Momentum: Reflects big-pharma push into next-gen RNAi therapeutics.
|
|
| |
Strategic Focus
|
| |
| • | Pipeline Acceleration: Supercharges Genentech’s RNAi/gene silencing portfolio.
|
|
| • | Platform De-Risking: Positions SanegeneBio for follow-on partnerships and funding.
|
|
| • | Market Scale: RNAi sector booming (projected $15B+ by 2030) amid oligo advances.
|
|
| • | Unmet Need Fit: Targets diseases ripe for precision RNAi intervention.
|
|
| |
This partnership propels the program to clinic, cementing Genentech’s leadership in gene modulation and SanegeneBio’s biotech rise.
|
| |
Lilly Expands Peptide Pipeline: Zonsen PepLib Enters Global Discovery Partnership
|
| |
Zonsen PepLib Biotech has entered a worldwide R&D and licensing agreement with Eli Lilly for peptide-based drug candidates using PepLib’s peptide libraries and proprietary discovery platforms.
|
| |
Why It Matters
|
| |
| • | Global R&D Split: PepLib on discovery; Lilly drives clinic/commercialization worldwide.
|
|
| • | Robust Economics: Upfront/near-term + milestones + royalties for PepLib.
|
|
| • | Platform Strength: Leverages expansive peptide libraries for rapid hit identification.
|
|
| • | Sector Momentum: Fuels confidence in peptides as versatile drug modality.
|
|
| |
Strategic Focus
|
| |
| • | Pipeline Diversification: Enhances Lilly’s peptide/oligonucleotide arsenal.
|
|
| • | Tech Showcase: Validates PepLib’s libraries for big-pharma collaborations.
|
|
| • | Market Growth: Peptide therapeutics market surging (projected $50B+ by 2030).
|
|
| • | Innovation Edge: Addresses complex targets beyond small molecules/biologics.
|
|
| |
This alliance accelerates peptide candidates to market, strengthening Lilly’s discovery engine and PepLib’s partnership profile.
|
| |
ZipBio Licenses AAV Gene Therapy to MeiraGTx for Geographic Atrophy
|
| |
|
| |
ZipBio has granted MeiraGTx an exclusive license for an AAV-based gene therapy program targeting Geographic Atrophy (GA), a leading cause of vision loss.
|
| |
Why It Matters
|
| |
| • | Exclusive Rights: MeiraGTx leads global development of AAV-GA program.
|
|
| • | Synergistic Tech: AI proteins (COMPACT) + proven AAV vectors/manufacturing.
|
|
| • | Undisclosed Economics: Upfront + milestones/royalties signal strong valuation.
|
|
| • | Mode Convergence: Blends AI, gene therapy for ophthalmic unmet needs.
|
|
| |
Strategic Focus
|
| |
| • | Ophthalmology Push: Bolsters MeiraGTx’s GA/AMD pipeline amid regulatory wins.
|
|
| • | AI Validation: Spotlights ZipBio’s COMPACT platform for protein therapeutics.
|
|
| • | Market Potential: GA market exploding ($10B+ peak sales forecast by 2030).
|
|
| • | Innovation Fusion: Accelerates de novo proteins in hard-to-drug vision diseases.
|
|
| |
This partnership fast-tracks AI-optimized gene therapy to clinic, enhancing MeiraGTx’s genetic medicines leadership and ZipBio’s AI-biotech footprint.
|
| |
Biomica Licenses Phase I Asset BMC128 to Lishan Biotech Globally
|
| |
Biomica (Evogene subsidiary) has signed an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a Phase I therapeutic candidate.
|
| |
Why It Matters
|
| |
| • | Global Exclusive Rights: Lishan leads worldwide development/commercialization.
|
|
| • | Clinical Momentum: Transitions Phase I asset to Phase II with China/US filings.
|
|
| • | Attractive Economics: Milestones + royalties for Biomica.
|
|
| • | China-West Bridge: Links Israeli innovation with Chinese biopharma execution.
|
|
| |
Strategic Focus
|
| |
| • | Pipeline Acceleration: Fast-tracks Lishan’s clinical portfolio expansion.
|
|
| • | Microbiome Validation: Reinforces Biomica/Evogene’s therapeutic platform.
|
|
| • | Market Access: Targets high-value indications via dual China/US strategy.
|
|
| • | Geographic Synergy: China manufacturing scale meets global regulatory ambitions.
|
|
| |
This license propels BMC128 toward Phase II/approval, amplifying Lishan’s global ambitions and Biomica’s microbiome leadership.
|
| |
Immuno-Oncology Expansion in Japan: Eisai & Henlius Sign Serplulimab Licensing and Commercialization Deal
|
| |
|
| |
Eisai and Henlius have signed an exclusive commercialization (Eisai) and co-exclusive development/manufacturing license for serplulimab (Hetronifly in EU) in Japan.
|
| |
Why It Matters
|
| |
| • | Japan Commercial Rights: Eisai handles exclusive sales; Henlius co-develops/manufactures.
|
|
| • | Lucrative Terms: $75M upfront + $313M milestones + double-digit royalties.
|
|
| • | Clinical Readiness: Phase II bridging supports FY2026 SCLC filing.
|
|
| • | Multi-Indication Play: Extends to mCRC and gastric cancer in Japan/globally.
|
|
| |
Strategic Focus
|
| |
| • | Oncology Expansion: Bolsters Eisai’s Japan immuno-oncology footprint.
|
|
| • | Geographic Bridge: Leverages Henlius’ China/EU data for Japan entry.
|
|
| • | Market Timing: Aligns with PD-1 demand in SCLC/gastric (>$5B Japan potential).
|
|
| • | Regulatory Efficiency: Bridging strategy accelerates multi-indication approvals.
|
|
| |
This partnership fast-tracks serplulimab’s Japan launch, enhancing Eisai’s oncology portfolio and Henlius’ global reach.
|
| |
|
| |
| | Phase III Wins and Pipeline Leaps Signal a New Wave of Therapeutic Momentum
|
|
|
|
|
| |
Phase III LEAP2MONO Study by Sanofi
|
| |
|
| |
Gaucher Disease Type 3
|
| |
Sanofi reports positive Phase III LEAP2MONO topline results: venglustat (once-daily oral) vs. enzyme replacement therapy (biweekly IV) in 43 patients aged ≥12 years with Gaucher disease type 3 (GD3).
|
| |
Key Details
|
| |
| • | Results: Met primary endpoint (improved neurological symptoms via modified SARA total score and RBANS at Week 52). Achieved 3/4 key secondary endpoints: reduced spleen/liver volume; improved hemoglobin levels.
|
|
| • | Next Steps: Plans global regulatory filings based on data.
|
|
| • | Asset: Oral alternative to IV therapy; also in Fabry disease (Phase III PERIDOT missed primary endpoint but relieved neuropathic/abdominal pain; CARAT ongoing for left ventricular mass index).
|
|
| |
These results advance oral options for GD3 treatment.
|
| |
Type 2 Diabetes
|
| |
Novo Nordisk reports positive Phase III topline results for CagriSema (once-weekly SC fixed-dose combo of cagrilintide + semaglutide; doses: 2.4/2.4 mg and 1/1 mg) in 2,728 patients with T2D uncontrolled on metformin ± SGLT2i (vs. semaglutide alone, cagrilintide alone, placebo).
|
| |
Key Details
|
| |
| • | Results (68 weeks, 2.4/2.4 mg): Superior to semaglutide 2.4 mg with HbA1c reduction of -1.91% vs. -1.76% (vs. -0.09% placebo); weight loss of -14.2% vs. -10.2% (vs. -1.5%; no plateau). 43% achieved ≥15% weight loss; 24% ≥20%. Treatment-regimen estimand: HbA1c -1.80% vs. -1.68%; weight -12.9% vs. -9.2%.
|
|
| • | Next Steps: Regulatory discussions planned for T2D; REIMAGINE 2 data expected 2026. Weight management submission already filed.
|
|
| • | Asset: Combines amylin analog + GLP-1 RA for enhanced glycemic/weight control.
|
|
| |
These data position CagriSema as a potential T2D leader.
|
| |
Obesity
|
| |
|
| |
Pfizer reports positive Phase IIb VESPER-3 topline results: PF-3944 (QW titration to QM dosing) in adults with obesity/overweight (no T2D) across multiple arms vs. placebo.
|
| |
Key Details
|
| |
| • | Results (Week 28, efficacy estimand): Up to 12.3% placebo-adjusted weight loss; Arms 1/3 achieved 10%/12.3% reductions (sustained, no plateau post-QM transition). Full data at ADA 2026.
|
|
| • | Next Steps: Arms 1/3 advance to Phase III; >20 obesity trials planned for 2026 (10 Phase III for PF-3944), including VESPER-4/5 (QW ±T2D) and VESPER-6 (QM), plus 7+ for comorbidities/flexibility/access.
|
|
| • | Asset: Novel dosing enables monthly maintenance for weight management.
|
|
| |
These findings accelerate Pfizer's obesity portfolio expansion.
|
| |
B-cell Non-Hodgkin Lymphoma
|
| |
Daiichi Sankyo doses first patient in Phase I/II trial of DS-3790 (CD37-targeted ADC) in ~420 patients with relapsed/refractory B-cell NHL.
|
| |
Key Details
|
| |
| • | Design: Evaluates safety and antitumor activity. Key efficacy endpoints: ORR, DCR, DoR, TTR, PFS, OS.
|
|
| • | Next Steps: Ongoing enrollment for dose escalation/expansion.
|
|
| • | Asset: Uses proprietary DXd platform (humanized anti-CD37 IgG1 mAb + cleavable linker + exatecan-derived topo I inhibitor payload) for tumor-selective cytotoxicity.
|
|
| |
This trial expands Daiichi Sankyo's ADC pipeline in hematologic malignancies.
|
| |
Secondary Stroke Prevention
|
| |
Bayer reports positive Phase III OCEANIC-STROKE topline results: asundexian (50 mg QD oral) + standard antiplatelet vs. placebo in 12,327 patients post-non-cardioembolic ischemic stroke/high-risk TIA.
|
| |
Key Details
|
| |
| • | Results: 26% reduction in recurrent ischemic stroke (no increase in ISTH major bleeding); consistent across subgroups. Met key secondary: 26% lower risk of any stroke (ischemic/hemorrhagic). Favorable composites (CV death/MI/stroke; all-cause death/MI/stroke). Full data at ISC 2026.
|
|
| • | Next Steps: Regulatory preparations anticipated.
|
|
| • | Asset: Oral Factor XIa inhibitor for safer anticoagulation in stroke prevention.
|
|
| |
These outcomes position asundexian as a potential new standard.
|
| |
|
| |
| | Regulatory Momentum Surges: Global Agencies Advance Next-Wave Therapies
|
|
|
|
|
| |
Accelerating Innovation: Regulatory Agencies Greenlight Next-Generation Therapies
|
| |
|
| |
Regulators across the US, Europe, and China delivered a wave of high-impact decisions, signaling strong progress for innovative therapies spanning cancer, rare genetic disorders, immunology, and respiratory disease. From CHMP positive opinions and FDA Priority Reviews to Breakthrough Therapy Designations and new approvals, this week’s regulatory actions underscore accelerating pathways for treatments addressing serious, high-unmet-need conditions, bringing multiple late-stage assets closer to patients worldwide.
|
| |
| • | Sanofi received a positive CHMP opinion for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD).
|
|
| • | UCB reported a positive CHMP opinion for Kygevvi (doxecitine + doxribtimine) for patients with thymidine kinase 2 deficiency (TK2d).
|
|
| • | Johnson & Johnson gained a positive CHMP opinion for Akeega in metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
| • | The CHMP recommended approval of Incyte’s Zynyz for squamous cell carcinoma of the anal canal (SCAC).
|
|
| • | Daiichi Sankyo and AstraZeneca announced US FDA Priority Review for Datroway in metastatic triple-negative breast cancer (TNBC).
|
|
| • | Exelixis reported US FDA acceptance of its NDA for zanzalintinib + Tecentriq in metastatic colorectal cancer (mCRC).
|
|
| • | Relay Therapeutics received US FDA Breakthrough Therapy Designation for zovegalisib in PIK3CA-mutant advanced breast cancer.
|
|
| • | GSK secured European Commission approval for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
|
|
| • | Kelun-Biotech received NMPA approval for sacituzumab tirumotecan in HR+/HER2– breast cancer.
|
|
| • | Akeso announced NMPA Breakthrough Therapy Designation for ivonescimab + chemotherapy in biliary tract cancer.
|
|
| |
|
| |
| | Accelerating Innovation: Next-Generation Diagnostics Advance Toward Approval
|
|
|
|
|
| |
Precision Tools in Focus: MedTech Innovation Gains Regulatory Momentum
|
| |
|
| |
The MedTech landscape is gaining speed as companies push next-generation diagnostics and precision tools closer to clinical adoption. Recent FDA-focused milestones highlight progress in cancer monitoring, neurodegenerative disease detection, and women’s health screening, underscoring how advanced testing platforms and algorithm-driven diagnostics are reshaping earlier detection, treatment decisions, and patient care pathways.
|
| |
| • | Natera is seeking US FDA approval for Signatera Cdx to support MRD-guided treatment decisions in bladder cancer, expanding the clinical utility of personalized molecular residual disease monitoring.
|
|
| • | Quanterix has submitted for US FDA approval of a multi-analyte, algorithm-based blood test designed to aid in the diagnosis of Alzheimer’s disease, advancing less invasive detection strategies in neurodegeneration.
|
|
| • | Hologic received US FDA approval for its Aptima HPV assay for primary HPV screening, strengthening molecular testing options in cervical cancer prevention.
|
|
| |
|
| |
| | Biosimilars Momentum: Alvotech Expands Globally and Advances Entyvio Rival Program
|
|
|
|
|
| |
Alvotech Drives Biosimilar Growth with Global Expansion and Competitive Pipeline Moves
|
| |
|
| |
Alvotech is accelerating its biosimilars strategy on two fronts, commercial reach and clinical progress.
|
| |
The company has signed supply and commercialization agreements with Sandoz covering multiple biosimilar candidates across Canada, Australia, and New Zealand. The partnership spans an ophthalmology biosimilar in Canada and three immunology and gastroenterology candidates in Australia and New Zealand. Alvotech will lead development and manufacturing, while Sandoz will drive regulatory filings and commercialization in these markets.
|
| |
On the pipeline side, Alvotech reported positive topline PK data for AVT80, its subcutaneous Entyvio biosimilar. The pivotal study confirmed pharmacokinetic similarity, supporting AVT80’s biosimilar profile. Along with AVT16 (IV), AVT80 forms part of Alvotech’s dual-route strategy to compete in the vedolizumab market.
|
| |
|
| |
| | Digital Health Meets Early Detection: Hims & Hers Expands Access to Multi-Cancer Screening
|
|
|
|
|
| |
Digital Health Advances: Hims & Hers Expands Access to Multi-Cancer Screening
|
| |
|
| |
Hims & Hers Health has introduced access to the Multi-Cancer Early Detection Test by Galleri, bringing advanced blood-based cancer screening into a consumer-focused care model.
|
| |
The test is designed to detect a shared cancer signal across 50+ cancer types including several without routine screening options, and can be taken annually to help identify disease earlier, often before symptoms emerge.
|
| |
By combining Hims & Hers’ broad digital health reach with GRAIL’s cutting-edge cancer detection technology, the initiative aims to widen access to proactive, data-driven early cancer screening and reshape how preventive oncology reaches patients.
|
| |
|
| |
| | Boehringer Ingelheim’s Ivomec Authorized to Help Prevent New World Screwworm in Cattle
|
|
|
|
|
| |
Boehringer Ingelheim Expands Cattle Health Solutions with Ivomec EUA
|
| |
|
| |
Boehringer Ingelheim has secured a US FDA Emergency Use Authorization (EUA) for Ivomec (ivermectin) 1% Injection to help prevent infestations caused by New World screwworm (NWS) in cattle, a significant step in livestock health protection.
|
| |
Under the EUA, Ivomec is authorized for NWS prevention when administered at key risk points, including within 24 hours of birth, at castration, or when wounds are identified, with exclusions for dairy cattle producing milk and veal calves.
|
| |
Based on the available scientific data, the FDA concluded that Ivomec demonstrated preventive benefit at these critical intervention stages, marking the first EUA granted for an over-the-counter product for NWS prevention in cattle, reinforcing the role of timely treatment in protecting herd health and agricultural stability.
|
| |
|
| |
| | ViVE 2026: Where Healthcare Leadership Meets Technology
|
|
|
|
|
| |
|
| |
ViVE 2026 is returning to Los Angeles, bringing together over 9,000 executives from across the healthcare ecosystem to explore the future of digital health and innovation. Co-created by HLTH Inc. and CHIME, the event is the premier forum where health system and payer leaders connect with innovators, investors, and solution providers driving measurable transformation in healthcare delivery.
|
| |
This is where CIOs, CTOs, CMIOs, and digital health executives come to accelerate strategy, evaluate what truly works, and build collaborations beyond the noise. In just a few days, ViVE delivers insights and connections that would otherwise take months to achieve.
|
| |
Attendees can expect thought-provoking sessions, hands-on demonstrations, and peer-to-peer networking with leaders shaping the next era of healthcare technology. From breakthrough solutions in telehealth, AI, and patient engagement to strategic discussions on digital transformation and operational efficiency, ViVE 2026 provides an immersive environment for actionable insights.
|
| |
Whether you’re looking to discover new technologies, foster partnerships, or gain executive-level insights, ViVE is the destination for those shaping what’s next in healthcare.
|
| |
Exclusive for the PharmaShots community:
|
| |
| • | Get $250 off ViVE General Attendee passes
|
|
| • | Use discount code: V26PHARMASHOTS
|
|
|
| |
Los Angeles | 2026 – don’t miss your chance to be part of the future of digital health.
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
Next-Gen Biotech Surge: Big Pharma Doubles Down on Degraders, RNAi, Peptides & Gene Therapy
|
| |
This week’s landscape shows an industry racing toward precision modalities and platform-driven innovation. Ipsen, Genentech, Lilly, and MeiraGTx placed major bets across protein degradation, RNAi, peptide therapeutics, and AI-designed gene therapy, while billion-dollar financing, global licensing pacts, and late-stage clinical wins signal strong capital confidence. Breakthrough Phase III data in metabolic, cardiovascular, and rare diseases, expanding ADC and immuno-oncology pipelines, and a wave of regulatory momentum across the US, EU, and China further highlight acceleration toward commercialization. From biosimilars and diagnostics to digital cancer screening and regenerative medicine, the ecosystem is converging on high-value, tech-enabled therapies aimed at large markets and high unmet needs — pushing multiple next-wave platforms closer to patients worldwide.
|
| |
Stay Ahead with PharmaShots Weekly
|
| |
Biopharma doesn’t pause and neither should your insight stream. PharmaShots Weekly distills the industry’s most important movements pipelines, regulatory decisions, competitive shifts, clinical breakthroughs, and strategic deals into a sharp, executive-ready brief you can absorb in minutes, not hours.
|
| |
Every Monday at 8:00 AM EST, you get a clear, decision-focused snapshot of what’s shaping global pharma and biotech. If this issue sparked ideas, turn that momentum into a habit. Subscribe to PharmaShots Weekly for intelligence that’s concise, credible, and built for leaders who don’t have time for fragmented noise.
|
| |
Know someone in R&D, Competitive Intelligence, Strategy, or Business Development who values signal over clutter? Forward this edition.
Found an insight worth spotlighting? Share it on LinkedIn and tag us we’re always glad to amplify sharp perspectives.
|
| |
The industry moves fast. Your intelligence should move faster.
|
| |
| | Questions?
Reach out to us [email protected] for any collaboration comments, questions, and media inquiry.
|
|
|
|
|
| |
|
0 comments